VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)

Study Summary

This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults with Type 2 Diabetes who are obese or overweight

Conditions

Weight Loss

Interventions / Drugs

VK2735

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment1100 participants

Primary Completion—

Lead SponsorViking Therapeutics, Inc.

Data Retrieved2026-04-11 04:31:01.273908+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.